Pablo Monteagudo-Mesas

Pablo Monteagudo-Mesas

Auto-generated profile, based on publicly available information

Pablo Monteagudo-Mesas

Flomics Biotech, SL, Carrer de Roc Boronat 31, 08005 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
JSJianfeng Sun
Jianfeng Sun
MPMartin Philpott
Martin Philpott
DLDanson Loi
Danson Loi
SLShuang Li
Shuang Li
PMPablo Monteagudo-Mesas
Pablo Monteagudo-Mesas
ACAdam Cribbs
Adam Cribbs
Unique molecular identifiers are random oligonucleotide sequences that remove PCR amplification biases. However, the impact that PCR associated sequencing errors have on the accuracy of generating absolute counts of RNA molecules is underappreciated. We show that PCR errors are a source of inaccuracy in both bulk and single-cell sequencing data, and synthesizing unique molecular identifiers using homotrimeric nucleotide blocks provides an error-correcting solution that allows absolute counting of sequenced molecules.

30 May 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PMPablo Monteagudo-Mesas
Pablo Monteagudo-Mesas
CBCornelia Brönner
Cornelia Brönner
PKParastou Kohvaei
Parastou Kohvaei
HAHaris Amedi
Haris Amedi
SCStefan Canzar
Stefan Canzar
MHMario Halic
Mario Halic
Heterochromatic silencing is thought to occur through a combination of transcriptional silencing and RNA degradation, but the relative contribution of each pathway is not known. In this study, we analyzed RNA Polymerase II (RNA Pol II) occupancy and levels of nascent and steady-state RNA in different mutants of Schizosaccharomyces pombe, in order to quantify the contribution of each pathway to heterochromatic silencing. We found that transcriptional silencing consists of two components, reduced RNA Pol II accessibility and, unexpectedly, reduced transcriptional efficiency. Heterochromatic loci showed lower transcriptional output compared to euchromatic loci, even when comparable amounts of RNA Pol II were present in both types of regions. We determined that the Ccr4–Not complex and H3K9 methylation are required for reduced transcriptional efficiency in heterochromatin and that a subset of heterochromatic RNA is degraded more rapidly than euchromatic RNA. Finally, we quantified the contribution of different chromatin modifiers, RNAi and RNA degradation to each silencing pathway. Our data show that several pathways contribute to heterochromatic silencing in a locus-specific manner and reveal transcriptional efficiency as a new mechanism of silencing.

11 July 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
LBLuka Borozan
Luka Borozan
FRFrancisca Rojas Ringeling
Francisca Rojas Ringeling
SKShao-Yen Kao
Shao-Yen Kao
ENElena Nikonova
Elena Nikonova
PMPablo Monteagudo-Mesas
Pablo Monteagudo-Mesas
SCStefan Canzar
Stefan Canzar
Alternative splicing (AS) of introns from pre-mRNA produces diverse sets of transcripts across cell types and tissues, but is also dysregulated in many diseases. Alignment-free computational methods have greatly accelerated the quantification of mRNA transcripts from short RNA-seq reads, but they inherently rely on a catalog of known transcripts and might miss novel, disease-specific splicing events. By contrast, alignment of reads to the genome can effectively identify novel exonic segments and introns. Event-based methods then count how many reads align to predefined features. However, an alignment is more expensive to compute and constitutes a bottleneck in many AS analysis methods. Here, we propose fortuna, a method that guesses novel combinations of annotated splice sites to create transcript fragments. It then pseudoaligns reads to fragments using kallisto and efficiently derives counts of the most elementary splicing units from kallisto’s equivalence classes. These counts can be directly used for AS analysis or summarized to larger units as used by other widely applied methods. In experiments on synthetic and real data, fortuna was around 7× faster than traditional align and count approaches, and was able to analyze almost 300 million reads in just 15 min when using four threads. It mapped reads containing mismatches more accurately across novel junctions and found more reads supporting aberrant splicing events in patients with autism spectrum disorder than existing methods. We further used fortuna to identify novel, tissue-specific splicing events in Drosophila. fortuna source code is available at https://github.com/canzarlab/fortuna.

14 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CTCristina Tuñí-Domínguez
Cristina Tuñí-Domínguez
GAGiovanni Asole
Giovanni Asole
PMPablo Monteagudo-Mesas
Pablo Monteagudo-Mesas
ERElena Cristina Rusu
Elena Cristina Rusu
LCLluc Cabús
Lluc Cabús
JLJulien Lagarde
Julien Lagarde
Plasma cell-free RNA (cfRNA) is a promising source of non-invasive biomarkers, but its clinical translation is hindered by technical challenges and a lack of protocol standardization, which compromises reproducibility and comparability across studies. There is a need for a systematic evaluation of existing cfRNA-Seq workflows to understand the drivers of technical variability. Here, we address this gap by performing a comprehensive cross-study analysis of 2,166 cfRNA-Seq samples from 15 published studies and an in-house generated dataset, applying a uniform bioinformatics pipeline to enable a controlled comparison of experimental workflows. Our analysis reveals that the donor phenotype typically explains a negligible fraction of the transcriptomic variation, whose main determinants are technical – principally protocol choice, genomic DNA contamination levels and library diversity. Remarkably, this technical noise is so profound that variation within plasma cfRNA samples exceeds that found across a wide range of human tissues. Finally, we demonstrate that critical pre-analytical factors are often confounded with patient phenotypes, jeopardizing the validity of biomarker discovery efforts. Our work serves as a comprehensive benchmark of current cfRNA-Seq methodologies and provides evidence-based guidelines to improve experimental design. By highlighting the dominance of controllable technical factors, we offer a path towards more robust and reproducible cfRNA research.

4 July 2026 in medRxiv
Verified
Preprint
Open access
PMPablo Monteagudo-Mesas
Pablo Monteagudo-Mesas
LSLaura Sánchez
Laura Sánchez
GAGiovanni Asole
Giovanni Asole
BNBeatriz Neto
Beatriz Neto
CTCristina Tuñí-Domínguez
Cristina Tuñí-Domínguez
MWMarc Weber
Marc Weber
Colorectal cancer (CRC) screening remains limited by patient adherence and sub-optimal sensitivity for early-stage disease. While liquid biopsy has revolutionized cancer diagnostics, cfDNA-based methods often struggle with early-stage detection due to low analyte levels. Here, we present a robust cell-free RNA (cfRNA) platform for the early detection of CRC. Using a retrospective cohort of 255 healthy controls and 250 CRC patients, we implemented an optimized workflow featuring a RUVg-based normalization strategy to remove platelet-driven transcriptomic noise. We identified differentially expressed genes enriched in key CRC-associated biological pathways, including inflammation, EMT, and metabolic dysregulation. An XGBoost classifier trained on these features achieved a mean AUC of 0.92 in cross-validation and 0.89 in a validation cohort, demonstrating 67% sensitivity at 90% specificity. Notably, our platform showed particular efficacy in identifying early stage cancer (stage I and II), achieving 73.7% sensitivity at 90% specificity. These findings suggest that cfRNA profiling offers a powerful, non-invasive orthogonal approach to CRC screening, capable of overcoming the sensitivity limitations of DNA-based assays in early-stage disease.